GN Store Nord shares surge 36% on 17 bln crown hearing sale to Amplifon

GN Store Nord agreed to sell its Hearing business to Amplifon for DKK17bn (DKK12.6bn cash + 56m Amplifon shares), driving GN shares +36% and Amplifon shares down >10%. The divested unit had DKK7.21bn revenue and pro-forma EBITDA DKK1.19bn in 2025 and employs ~5,500; GN will hold ~16% of Amplifon post-close. Transaction requires merger approvals and a statutory demerger, expected by end-2026; GN plans to use proceeds to reduce debt, reinvest and return capital and has revised 2026 organic revenue guidance to 2–8% for Enterprise & Gaming while suspending long-term targets.

Analysis

This deal creates a clear bifurcation: the buyer inherits integration, financing and dilution risk while the seller transitions into a smaller, more capital-light conglomerate with concentrated optionality tied to the retained stake. Expect near-term market moves to be driven by funding optics and headline regulatory scrutiny rather than underlying end-market demand for hearing solutions.

Second-order winners will be scale-oriented suppliers and logistics partners that can absorb larger, consolidated volumes — small independent retail networks and niche component vendors will face margin pressure and potential contract repricing. Incumbent competitors that avoided this M&A churn can lean into claims of stability and execution, using the window while integration attention is elsewhere to steal share in key markets.

Main risks are regulatory remedies, financing repricing, and integration that dilutes projected synergies; each can overturn the re-rating in 3–12 months. For investors, the actionable timeframe is layered: trade volatility and position around regulatory milestones in the next 6–12 months, while positioning for structural industry consolidation outcomes across a 1–3 year horizon.

Key Decisions for Investors

• Long GN Store Nord (GN.CO) — 3–12 month directional. Rationale: retained stake ensures optionality plus balance-sheet flexibility; target 20–30% upside, stop-loss 12%. Size 3–5% of equity book; re-evaluate after next quarterly update on capital allocation.
• Pair trade: Short Amplifon (AMP.MI) / Long Sonova (SONN.SW) 0.8:1 — 6–12 month event hedge. Express view that buyer overpays and bears execution/leverage risk while a high-quality incumbent outperforms. Use equal dollar exposure scaled to volatility, set pair stop if spread tightens by 15%.
• Buy downside protection on Amplifon — purchase 9–12 month put spread (OTM) to limit cost while capturing regulatory/integration downside. Target 2–4x payoff vs premium if deal drags or goodwill impairments emerge; cap position at 1–2% portfolio risk.
• Event arb opportunism — monitor regulatory filings and financing notices; be ready to add mean-reversion trades on GN on any headline-driven pullbacks (size opportunistically up to 5% if price drops >15% intraday and liquidity normalizes).